Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00143208
Status:
COMPLETED
Last Update Posted:
2021-02-21
First Post:
2005-08-31
Brief Title:
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom Fixed Combination Of Latanoprost And Timolol In Patients With Poag Or Oh A 6-Month Open Multi-Center Trial In Italy
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination Xalacom after 6 month of treatment Eligible patients may be enrolled at the baseline visit All current ocular hypotensive therapy must be discontinued at this time On baseline day patients eligible for the study will receive Xalacom which is to be instilled in the morning
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None